Cabot (CBT) to Release Quarterly Earnings on Tuesday

Cabot (NYSE:CBT) is projected to post its Q1 2026 results after the market closes on Tuesday, February 3rd. Analysts expect Cabot to post earnings of $1.40 per share and revenue of $889.1120 million for the quarter. Cabot has set its FY 2026 guidance at 6.000-7.00 EPS. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:00 AM ET.

Cabot (NYSE:CBT) last released its quarterly earnings data on Monday, November 3rd. The specialty chemicals company reported $1.70 earnings per share for the quarter, missing the consensus estimate of $1.72 by ($0.02). Cabot had a net margin of 8.91% and a return on equity of 24.55%. The company had revenue of $899.00 million during the quarter, compared to the consensus estimate of $967.02 million. During the same quarter in the prior year, the company posted $1.80 earnings per share. The company’s revenue for the quarter was down 10.2% on a year-over-year basis. On average, analysts expect Cabot to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Cabot Price Performance

Cabot stock opened at $71.27 on Tuesday. The business has a 50 day simple moving average of $67.20 and a 200 day simple moving average of $71.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.61 and a quick ratio of 1.08. The company has a market capitalization of $3.77 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 3.82 and a beta of 0.89. Cabot has a one year low of $58.33 and a one year high of $89.37.

Cabot Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 12th. Shareholders of record on Friday, November 28th were issued a dividend of $0.45 per share. The ex-dividend date of this dividend was Friday, November 28th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.5%. Cabot’s dividend payout ratio (DPR) is presently 29.95%.

Institutional Investors Weigh In On Cabot

Several hedge funds and other institutional investors have recently made changes to their positions in CBT. NewEdge Advisors LLC raised its position in shares of Cabot by 2,559.5% during the first quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock worth $82,000 after acquiring an additional 947 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after purchasing an additional 108,645 shares during the last quarter. Empowered Funds LLC lifted its position in Cabot by 102.6% during the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after purchasing an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Cabot by 3.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after purchasing an additional 4,048 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its position in shares of Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after buying an additional 364 shares during the period. 93.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CBT has been the topic of several analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Cabot from $75.00 to $54.00 and set an “underweight” rating on the stock in a report on Friday, November 28th. Zacks Research lowered shares of Cabot from a “hold” rating to a “strong sell” rating in a research report on Friday, November 7th. Mizuho raised their price objective on shares of Cabot from $72.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 18th. UBS Group boosted their target price on Cabot from $65.00 to $74.00 and gave the stock a “neutral” rating in a report on Monday, January 12th. Finally, Jefferies Financial Group restated a “buy” rating and set a $81.00 price target on shares of Cabot in a research report on Thursday, January 8th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $72.25.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.